Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVES:In Fiji, autochthonous chikungunya virus (CHIKV) infection was first detected in March 2015. In a previous serosurvey conducted during October-November 2015, we reported a prevalence of anti-CHIKV IgG antibodies of 0.9%. In the present study, we investigated the seroprevalence of CHIKV two years after its emergence in Fiji. METHODS:Sera from 320 residents of Fiji recruited in June 2017, from the same cohort of individuals that participated in the serosurvey in 2015, were tested for the presence of IgG antibodies against CHIKV using a recombinant antigen-based microsphere immunoassay. RESULTS:Between 2015 and 2017, CHIKV seroprevalence among residents increased from 0.9% (3/333) to 12.8% (41/320). Of the participants with available serum samples collected in both 2015 and 2017 (n=200), 31 (15.5%) who were seronegative in 2015 had seroconverted to CHIKV in 2017. CONCLUSIONS:Our findings suggest that low-level transmission of CHIKV occurred during the two years following the emergence of the virus in Fiji. No CHIKV infection has been reported in Fiji since 2017, but due to the presumed low herd immunity of the population, the risk of CHIKV re-emergence is high. Consequently, chikungunya should be considered in the differential diagnosis of acute febrile diseases in Fiji.

Original publication

DOI

10.1016/j.ijid.2019.10.040

Type

Journal article

Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Publication Date

01/2020

Volume

90

Pages

223 - 225

Addresses

Institut Louis Malardé, PO BOX 30, 98713 Papeete, Tahiti, French Polynesia. Electronic address: maubry@ilm.pf.

Keywords

Humans, Chikungunya virus, Antibodies, Viral, Seroepidemiologic Studies, Immunity, Herd, Adolescent, Adult, Aged, Aged, 80 and over, Middle Aged, Child, Child, Preschool, Fiji, Female, Male, Young Adult, Chikungunya Fever, Seroconversion